8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

_______________________

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): September 5, 2019

ALEXION PHARMACEUTICALS, INC.

-----------------------------------------------------------

(Exact name of registrant as specified in its charter)

Delaware	000-27756	13-3648318
------------------	------------------	---------------
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

121 Seaport Boulevard, Boston, Massachusetts 02210

---------------------------------------------------------------

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code:    (475) 230-2596

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
☐	Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01    Other Events

On September 5, 2019, the European Patent Office determined, following examination proceedings, not to grant Alexion Pharmaceuticals, Inc.’s (the “Company”) European patent applications 3124029 and 3167888 which relate to the pharmaceutical compositions of SOLIRIS® (eculizumab) and composition of matter of SOLIRIS® (eculizumab), respectively. The Company will evaluate its option to appeal the European Patent Office’s decision with respect to these patent applications following receipt and review of the written decision.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 5, 2019	ALEXION PHARMACEUTICALS, INC.
	By:     /s/ Doug Barry
	Name:    Doug Barry
	Title:    Vice President, Corporate Law

XML

Cover Page Statement	Sep. 05, 2019
Cover page.
Entity Emerging Growth Company	false
Written Communications	false
Entity Incorporation, State or Country Code	DE
Entity Central Index Key	0000899866
Document Type	8-K
Document Period End Date	Sep. 05, 2019
Entity Registrant Name	ALEXION PHARMACEUTICALS, INC.
Entity Address, Address Line One	121 Seaport Boulevard
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02210
City Area Code	475
Local Phone Number	230-2596
Amendment Flag	false
Entity File Number	000-27756
Entity Tax Identification Number	13-3648318
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false